ArticleCureus2025

Maintenance Low-Dose BRAF Inhibition and Rituximab in Relapsed Hairy Cell Leukemia: A Therapeutic Alternative.

Anshul Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.